Arrowhead Pharmaceuticals, Inc. (ARWR)
NASDAQ: ARWR · IEX Real-Time Price · USD
22.12
+0.25 (1.14%)
At close: Apr 26, 2024, 4:00 PM
21.75
-0.37 (-1.67%)
After-hours: Apr 26, 2024, 7:22 PM EDT
Arrowhead Pharmaceuticals Employees
Arrowhead Pharmaceuticals had 525 employees on September 30, 2023. The number of employees increased by 128 or 32.24% compared to the previous year.
Employees
525
Change (1Y)
128
Growth (1Y)
32.24%
Revenue / Employee
$346,171
Profits / Employee
-$565,360
Market Cap
2.74B
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Sep 30, 2023 | 525 | 128 | 32.24% |
Sep 30, 2022 | 397 | 68 | 20.67% |
Sep 30, 2021 | 329 | 97 | 41.81% |
Sep 30, 2020 | 232 | 98 | 73.13% |
Sep 30, 2019 | 134 | 18 | 15.52% |
Sep 30, 2018 | 116 | 23 | 24.73% |
Sep 30, 2017 | 93 | -20 | -17.70% |
Sep 30, 2016 | 113 | 9 | 8.65% |
Sep 30, 2015 | 104 | 23 | 28.40% |
Sep 30, 2014 | 81 | 27 | 50.00% |
Sep 30, 2013 | 54 | 2 | 3.85% |
Sep 30, 2012 | 52 | 34 | 188.89% |
Sep 30, 2011 | 18 | 0 | - |
Sep 30, 2010 | 18 | -2 | -10.00% |
Sep 30, 2009 | 20 | -48 | -70.59% |
Sep 30, 2008 | 68 | 10 | 17.24% |
Sep 30, 2007 | 58 | 22 | 61.11% |
Sep 30, 2006 | 36 | -11 | -23.40% |
Sep 30, 2005 | 47 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
Company Name | Employees |
---|---|
Bausch Health Companies | 20,270 |
Amedisys | 19,000 |
Azenta | 3,500 |
LivaNova | 2,900 |
TransMedics Group | 584 |
Immunocore Holdings | 497 |
Xenon Pharmaceuticals | 259 |
Arcellx | 130 |
ARWR News
- 20 hours ago - Arrowhead Pharmaceuticals to Host 2024 Summer Series of R&D Webinars - Business Wire
- 2 days ago - Arrowhead Pharmaceuticals to Webcast Fiscal 2024 Second Quarter Results - Business Wire
- 2 days ago - Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-CFB for Treatment of Complement Mediated Kidney Disease - Business Wire
- 19 days ago - Arrowhead Pharmaceuticals Announces New Phase 2 Data of Plozasiran Published in JAMA Cardiology and Presented at American College of Cardiology 73rd Annual Scientific Session & Expo - Business Wire
- 25 days ago - Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) - Business Wire
- 4 weeks ago - Arrowhead Pharmaceuticals Initiates Expanded Access Program for Plozasiran and Announces Upcoming Presentation of Clinical Data - Business Wire
- 7 weeks ago - Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-DM1 for Treatment of Type 1 Myotonic Dystrophy - Business Wire
- 7 weeks ago - Arrowhead Pharmaceuticals to Participate in Upcoming March 2024 Conferences - Business Wire